Heilongjiang ZBD Pharmaceutical Co Ltd - Asset Resilience Ratio
Heilongjiang ZBD Pharmaceutical Co Ltd (603567) has an Asset Resilience Ratio of 0.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Heilongjiang ZBD Pharmaceutical Co Ltd for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Heilongjiang ZBD Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See 603567 net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Heilongjiang ZBD Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Heilongjiang ZBD Pharmaceutical Co Ltd market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥463.76K | 0.0% |
| Total Liquid Assets | CN¥463.76K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Heilongjiang ZBD Pharmaceutical Co Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Heilongjiang ZBD Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Heilongjiang ZBD Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521 |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE |
Drug Manufacturers - Specialty & Generic | 1.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 2.69% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 20.24% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
Annual Asset Resilience Ratio for Heilongjiang ZBD Pharmaceutical Co Ltd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Heilongjiang ZBD Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | CN¥537.23K ≈ $78.61K |
CN¥12.71 Billion ≈ $1.86 Billion |
+0.00pp |
| 2023-12-31 | 0.00% | CN¥427.03K ≈ $62.49K |
CN¥12.47 Billion ≈ $1.82 Billion |
0.00pp |
| 2022-12-31 | 0.00% | CN¥505.09K ≈ $73.91K |
CN¥11.68 Billion ≈ $1.71 Billion |
-6.16pp |
| 2016-12-31 | 6.17% | CN¥396.00 Million ≈ $57.95 Million |
CN¥6.42 Billion ≈ $939.30 Million |
-- |
About Heilongjiang ZBD Pharmaceutical Co Ltd
Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthopedics, tumors, digestive system, anti-infection, mental nerve, genitourinary, and other disease fields. The company was founded in 1996 and is based in Hulin, China.